Human Apolipoprotein C-III (Apo C3) ELISA Kit (with Control)

$453.00

Catalog Number: EA8133-7

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.
Product Size:96 Well Plate

Additional information

Format

Sandwich ELISA

Entrez Gene

345

Components

Biotinylated Human Apolipoprotein C-III Antibody, Chromogen Substrate (1x), EIA Diluent Concentrate (10x), Human Apolipoprotein C-III Microplate, Human Apolipoprotein C-III Standard, Positive Control, Sealing Tapes, SP Conjugate (100x), Stop Solution (1x), Wash Buffer Concentrate (20x)

TIme

4 hours

Sensitivity

1.1 ng/ml

Range

1.95 – 500 ng/ml

Samples Type

CSF, Milk, Plasma, Serum, Urine

Associated Disease

Cancer, Cardiovascular, Metabolism

Species

Human

UniProt

P02656

Storage

Refer to component labels for details

Plex

1

Usage

For Research Use Only, Not To Be Used For Diagnostic Purposes

Documentation

Publications (56 results)

Please use discretion when following external links; Assaypro cannot guarantee the validity and security of all citation links provided.

Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum

High-dose DHA has more profound effects on LDL-related features than high-dose EPA: the ComparED study

Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer's disease

Cyclodextrin?micellar electrokinetic chromatography of apolipoproteins on human very low?density lipoprotein

Human apolipoprotein CIII levels; evaluation of three assay methods. Scandinavian Journal of Clinical and Laboratory Investigation

Effects of acute exercise on monocyte subpopulations in metabolic syndrome patients

Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes

High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study

Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism

ANGPTL3 serum concentration and rare genetic variants in Finnish population

CHARACTERIZATION OF ANGPTL3 DEFICIENCY AND MOLECULAR MECHANISMS OF ANGPTL3 DEFICIENCYINDUCED HYPOLIPIDEMIA

Prevalence and Genetics of Non-Alcoholic Fatty Liver Disease

QUANTITATIVE DETERMINATION OF PROTEIN APOCIII IN SERUM: COMPARISON OFTHREE ASSAY METHODS

Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism

Effect of Mediterranean Diet With and Without Weight Loss on Apolipoprotein B100 Metabolism in Men With Metabolic Syndrome

Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling

Biomarkers for monitoring treatment of neuropsychiatric diseases

Impaired lipid transport in gestational diabetes mellitus

Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response

Apo E Derived from Adipose Tissue Does Not Suppress Atherosclerosis or Correct Hyperlipidemia in EKO Mice

Longitudinal Analysis of Maternal Plasma Apolipoproteins in Pregnancy: A Targeted Proteomics Approach

An Apolipoprotein CIII-Derived Peptide, Hatktak, Activates Macromolecular Activators of Phagocytosis from Platelets (MAPPs). Lipoproteins - Role in Health and Diseases

Biomarkers for monitoring treatment of neuropsychiatric diseases

Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease

Development of a Sensitive ELISA to Quantify Apolipoprotein CIII in Non-human Primate Serum

Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study

The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis

Elevated Ratio of Maternal Plasma ApoCIII to ApoCII in Preeclampsia

* Hu Y et al. (2021) Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer's disease. J Lipid Res. 62:100014.

* Shieh YT et al. (2020) Cyclodextrin?micellar electrokinetic chromatography of apolipoproteins on human very low?density lipoprotein. Electrophoresis. 41(15):1333-1343.

* Sandin A et al. (2020) Human apolipoprotein CIII levels; evaluation of three assay methods. Scandinavian Journal of Clinical and Laboratory Investigation. Scand J Clin Lab Invest. 80(3):230-235

* Wonner R et al. (2018) Effects of acute exercise on monocyte subpopulations in metabolic syndrome patients. Cytometry B Clin Cytom. 94(4):596-605.

* Colombo M et al. (2018) Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis.274:182-190

* Allaire J et al. (2018) High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study. J Clin Endocrinol Metab. 103(8):2909-2917.

* Watts GF (2017) Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation. 135(4):338-351.

* Tikka A et al. (2017) ANGPTL3 serum concentration and rare genetic variants in Finnish population. Scand J Clin Lab Invest. 77(8):601-609.

* Tikka A (2017) CHARACTERIZATION OF ANGPTL3 DEFICIENCY AND MOLECULAR MECHANISMS OF ANGPTL3 DEFICIENCYINDUCED HYPOLIPIDEMIA. University of Helsinki.

* Hyysalo J (2017) Prevalence and Genetics of Non-Alcoholic Fatty Liver Disease. University of Helsinki.

* Sandin A et al. (2015) QUANTITATIVE DETERMINATION OF PROTEIN APOCIII IN SERUM: COMPARISON OFTHREE ASSAY METHODS. Clin. Chem Lab Med 2015:53, Special Suppl, pp S248

* Chan DC et al. (2015) Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. Clin Sci (Lond). 128(6):379-85.

* Bridge SH et al.(2015) PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol. 2015 Apr;62(4):763-70.

* Richard C et al. (2014) Effect of Mediterranean Diet With and Without Weight Loss on Apolipoprotein B100 Metabolism in Men With Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 34:433-438

* Riwanto M et al. (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation. 127(8):891-904

* Pi B and Bilello J (2013) Biomarkers for monitoring treatment of neuropsychiatric diseases. Patent application EP20110846638

* Nichols SKF et al. (2013) Impaired lipid transport in gestational diabetes mellitus. Journal of Diabetes Research & Clinical Metabolism. doi: 10.724/2050-0866-2-22

* Lee JH et al. (2013) Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response. Am J Reprod Immunol. 2013 Oct;70(4):265-84. doi: 10.1111/aji.12142. Epub 2013 Jul 30

* Huang ZH et al. (2013) Apo E Derived from Adipose Tissue Does Not Suppress Atherosclerosis or Correct Hyperlipidemia in EKO Mice. J. Lipid Res. 54(1):202-213.

* Flood-Nichols SK et al. (2013) Longitudinal Analysis of Maternal Plasma Apolipoproteins in Pregnancy: A Targeted Proteomics Approach. Molecular & Cellular Proteomics 12.1

* Sakamoto H et al. (2012) An Apolipoprotein CIII-Derived Peptide, Hatktak, Activates Macromolecular Activators of Phagocytosis from Platelets (MAPPs). Lipoproteins - Role in Health and Diseases. Chapter 31. p.721-740

* Pi B et al. (2012) Biomarkers for monitoring treatment of neuropsychiatric diseases. Patent application number: US20120178118 A1

* Hyysalo J (2012) Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012 May;27(5):951-956

* Wang Y et al. (2011) Development of a Sensitive ELISA to Quantify Apolipoprotein CIII in Non-human Primate Serum. J Lipid Res. 52(6):1265-1271

* Papakostas GI (2011) Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. Mol Psychiatry 18(3):332-9.

* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062.

* Flood-Nichols SK et al. (2011) Elevated Ratio of Maternal Plasma ApoCIII to ApoCII in Preeclampsia. Reprod Sci. 18(5):493-502.

Loading data...